Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review

IF 2 Q2 UROLOGY & NEPHROLOGY

Research and Reports in Urology Pub Date : 2023-11-01 DOI:10.2147/rru.s398129

Margaret Meagher, Amirali Salmasi, Tyler Stewart

引用次数: 0

Abstract

Abstract: With the advent of new therapeutic modalities, management of metastatic castrate-sensitive prostate cancer (mCSPC) has been in flux. From androgen-deprivation therapy to docetaxel to androgen receptor–signaling inhibitors, each agent has heralded a new treatment paradigm. As such, the optimal first-line therapy for mCSPC remains incompletely defined. This review provides a narrative of recent advances to systemic therapy within the mCSPC treatment space, particularly with regard to expansion to triplet therapy. Keywords: metastatic, castrate-sensitive prostate cancer, darolutamide

查看原文本刊更多论文

转移性去势敏感前列腺癌的治疗前景综述

摘要:随着新的治疗方式的出现，转移性去势敏感前列腺癌(mCSPC)的治疗一直在不断变化。从雄激素剥夺疗法到多西他赛再到雄激素受体信号抑制剂，每种药物都预示着一种新的治疗模式。因此，mCSPC的最佳一线治疗仍未完全确定。本文综述了mCSPC治疗领域中系统性治疗的最新进展，特别是扩展到三联疗法。关键词:转移性，去势敏感前列腺癌，达罗他胺

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Research and Reports in Urology UROLOGY & NEPHROLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Research and Reports in Urology is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease Investigation and treatment of urological disease Pharmacology of drugs used for the treatment of urological disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered.